Stories about Neonatal Fc receptor

Subscribe to Neonatal Fc receptor

09.09.2020 – 07:00

UCB Pharma
Final Phase II Results for UCB's Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances

Brussels (ots/PRNewswire) - - Phase II data demonstrated clinically meaningful platelet count increases with meaningful decreases in IgG concentration - Rozanolixizumab's subcutaneous route of administration shows potential to deliver targeted individualized patient care for people living with Primary Immune ...

more
27.07.2020 – 07:10

UCB Pharma
UCB Half Year Report 2020

Brussels (ots/PRNewswire) - - UCB's resilient product portfolio drives continued company growth - Revenue increased to EUR 2.6 billion and net sales to EUR 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively - Underlying profitability (adj. EBITDA) was EUR 783 million (+8%, 0% CER) or a ratio of 30% - Ra Pharma acquisition closed early April, Engage Therapeutics acquired in June, co-promotion agreement for Cimzia® with Ferring in July - ...

more
02.04.2020 – 15:34

UCB Pharma
UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

Brussels (ots/PRNewswire) - - The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab, UCB's FcRn targeting ...

more
10.12.2019 – 01:45

UCB Pharma
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...

more
10.10.2019 – 09:38

UCB Pharma
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

Brussels and Cambridge, Massachusetts (ots/PRNewswire) - - Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - ...

more
18.10.2018 – 07:01

UCB Pharma
UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

Brussels (ots/PRNewswire) - - Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints - Strong 68% mean reduction of Serum IgG and IgG Autoantibodies observed - Safety profile ...

more

1